Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pulmonary mucosa-associated lymphoid tissue lymphoma: Is gastric involvement underdiagnosed?

Cancer·2026

Same author

[Invasive mycoses in France: what are the trends?]

La Revue du praticien·2026

Same author

[Candidemia: the most frequent invasive fungal infection in France].

La Revue du praticien·2026

Same author

Antifungal exposure in <i>Scedosporium</i> septic arthritis: synovial penetration of voriconazole and terbinafine and plasma concentrations of olorofim.

Antimicrobial agents and chemotherapy·2026

Same author

Humans homozygous for rare or common hypomorphic IL23R variants are prone to tuberculosis.

The Journal of experimental medicine·2026

Same author

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Pneumocystis jirovecii Pneumonia.

Emilie Catherinot¹, Fanny Lanternier, Marie-Elisabeth Bougnoux

¹Université Paris Descartes, Service de Maladies Infectieuses et Tropicales, 149 Rue de Sèvres, Centre d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants Malades, Paris 75015, France.

Infectious Disease Clinics of North America

|February 23, 2010

Summary

Pneumocystis pneumonia (PCP) is a severe opportunistic infection, particularly in AIDS patients and those on immunosuppressants. This review covers its biology, diagnosis, and treatment, highlighting evolving epidemiology and pathophysiology.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Experiment Videos

Last Updated: Jun 16, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Area of Science:

Medical Mycology
Infectious Diseases
Immunology

Background:

Pneumocystis jirovecii (P. jirovecii) has emerged as a significant pathogen, especially with the HIV/AIDS epidemic.
Increased use of immunosuppressive therapies has also contributed to the rise of P. jirovecii infections.
Pulmonary infections caused by P. jirovecii, particularly Pneumocystis pneumonia (PCP), remain a critical clinical concern.

Purpose of the Study:

To provide a comprehensive summary of current knowledge regarding P. jirovecii.
To focus on the evolving pathophysiology and epidemiology of P. jirovecii infections.
To consolidate information on diagnosis, prevention, and treatment strategies for PCP.

Main Methods:

Literature review and synthesis of existing research on P. jirovecii.
Analysis of data related to the biology and clinical aspects of P. jirovecii.
Focus on recent developments in understanding P. jirovecii pathophysiology and epidemiology.

Main Results:

P. jirovecii infection is strongly associated with compromised immune systems, including HIV/AIDS.
The pathophysiology and epidemiology of P. jirovecii infections are dynamic and continue to evolve.
Pneumocystis pneumonia (PCP) is characterized by significant morbidity and mortality.

Conclusions:

Pneumocystis pneumonia remains a severe opportunistic infection with a high mortality rate.
Understanding the evolving aspects of P. jirovecii is crucial for effective management.
Continued research and vigilance are necessary to combat P. jirovecii infections.